

NUTRITION UNIT

Scientific Panel on Dietetic Products, Nutrition and Allergies Draft Agenda of the 59th plenary meeting 25-26 June 2014, 9 am – 6.30 pm, Parma 27 June 2014, 9 am – 1 pm, Parma

Meeting open to Observers on 26-27 June 2014
With the exception of 25 June 2014

25 June 2014: CLOSED SESSION

Starting at 9:00 on the 25th and finishing by 18:30 on the same day

- 1 Welcome and apologies for absence
- 2 Adoption of the agenda
- 3 Declarations of interest
- 4 Agreement of the minutes of the 58th Plenary meeting held on 8-11 April 2014
- 5 Report on written procedures since 58th Plenary meeting
- 6 Scientific outputs submitted for discussion and/or possible adoption

Applications pursuant to Article 14/13.5 of Regulation (EC) No 1924/2006 [Items 6.1-6.5 are closed to observers, owing to confidential business information/proprietary data]

- 6.1 DoubleGood AB "Table water containing a nutrient mix" and "contributes to the reduction of blood glucose rise when consumed together with a carbohydrate rich meal" (Art. 13.5, 0395_SE, <u>EFSA-Q-2013-00756</u>)
 For possible adoption
- 6.2 DSM Nutritional and Kemin Foods "Lutein together with zeaxanthin" and "helps maintain clarity and contrast of sight in bright light conditions" (Art. 13.5, 0399_FR, EFSA-Q-2013-00875)
 For possible adoption
- 6.3 InQpharm Europe Ltd "PhaseLiteTM" and "helps to reduce body weight" (Art. 13.5, 0403_UK, <u>EFSA-Q-2013-00973</u>)
 For possible adoption
- 6.4 Natural Alternatives International, Inc (NAI) "Beta-alanine" and "increase in performance during short-duration high intensity exercise" (Art. 13.5, 0404_UK, EFSA-Q-2013-00974)

For possible adoption

6.5 Clasado Limited - "Regular daily consumption of 1.37g galactooligosaccharides from Bimuno®" and "may reduce abdominal discomfort" (Art. 13.5, 0406_MT, EFSA-Q-2014-00022)

For possible adoption



Novel Foods [Items 6.6-6.7 are closed to observers, owing to confidential business information/proprietary data]

- **6.6 Draft Opinion on the safety of Astaxanthin** (EFSA-Q-2011-00990) For possible adoption
- **6.7 Draft Opinion on the safety of 'Cetyl Myristoleate Complex'** (EFSA-Q-2014-00166) For possible adoption

26-27 June 2014: OPEN SESSION

Starting at 9:00 on the 26th and finishing by 13:00 on the 27th

- 7 Brief introduction of Panel members and Observers, and presentation of the 'Guidelines for Observers'
- 8 New mandates
 - 8.1. Applications pursuant to Article 14/13.5 of Regulation (EC) no 1924/2006
 - 8.2. Other mandates
- 9 Scientific outputs submitted for discussion and/or possible adoption (cont.)

Dietary Reference Values

- 9.1 Draft technical report on the comments received during the public consultation for the draft DRVs for niacin (EFSA-Q-2013-01016)

 For discussion/possible endorsement
- 9.2 Draft of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to the dietary reference values for niacin (EFSA-Q-2011-01218)

For discussion/possible adoption

9.3 Draft Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to the dietary reference values for selenium (EFSA-Q-2011-01223)

For discussion/possible endorsement for release for public consultation

9.4 Draft Opinion of the Scientific Panel on Dietetic Products, Nutrition and Allergies on a request from the Commission related to the dietary reference values for folate (EFSA-Q-2011-01212)

For discussion/possible endorsement for release for public consultation

Others

- 9.5 Draft technical report on the comments received during the public consultation for the Draft on the composition of milk based-drinks and similar products intended for infants and young children (EFSA-Q-2014-00245)
 - For discussion/possible endorsement
- 9.6 Draft Opinion on the composition of milk based-drinks and similar products intended for infants and young children (EFSA-Q-2013-00264)

 For discussion/possible adoption
- 9.7 Draft Opinion on health benefits of fish and shellfish consumption in relation to health risks associated with exposure to methylmercury (EFSA-Q-2013-00167)

 For discussion/possible adoption
- **9.8 Draft opinion on Safety assessment of caffeine** (EFSA-Q-2013-00220) *For discussion*



- 10 Feedback from the Scientific Committee/the Scientific Panel, Working Groups, EFSA, the European Commission
 - 10.1 Scientific Committee and other Scientific Panels
 - 10.2 Working groups
 - 10.3 EFSA
 - 10.4 European Commission
- 11 Other scientific topics for information and/or discussion
- 12 Questions from Observers
- 13 Any other business